Medtech companies directory 2026

Medical Device Companies in China

Provincial volume-based procurement has turned Chinese hospital technology into a tender sport: a Class III NMPA certificate is the entry ticket, a winning provincial or alliance bid is the volume, and a domestic name that can service 300 county hospitals now beats a multinational brochure in more lots than Shanghai import teams like to admit.

Mindray, United Imaging, MicroPort, Weigao, Yuwell, Neusoft Medical and Shinva are the Chinese houses that already sit on county and tertiary capital lists. GE HealthCare, Siemens Healthineers and Philips still hold premium imaging and high-end monitoring seats in tier-1 teaching hospitals, but they now bid against domestic substitution language in the same provincial packages. Sinopharm’s device-distribution arms are the state wholesaler that many imported SKUs still ride after NMPA approval. The National Medical Products Administration in Beijing is the Class II/III gate; provincial bureaus run the local filing and the post-market inspections. BioNixus fields named tertiary and county accounts, not a single “China hospital” average.

Updated September 2026 · NMPA — National Medical Products Administration, medical device registration and supervision as of September 2026 · 16 named accounts

Request a proposal for China Browse the 16 companies

NMPA

National Medical Products Administration — Class II/III device gate in Beijing

VBP

Volume-based procurement alliances that reset implant and consumable prices by province

County

County-hospital upgrade programmes that now buy domestic imaging and monitoring first

Sinopharm

State distribution backbone many imported device SKUs still ride after approval

Named accounts

Top medical device companies in China

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against NMPA — National Medical Products Administration, medical device registration and supervision (as of 2026-09-05).

#	Company	HQ	Type	Device categories	Notes
01	NMPA (National Medical Products Administration)	Beijing	Government	Class II/III device registration, inspections and vigilance	The Beijing gate a Chinese legal entity must clear before a provincial tender committee will even open the bid envelope.
02	Sinopharm medical device distribution	Beijing / provincial hubs	Distributor	State wholesaler and hospital invoice path for imported and domestic devices	After NMPA approval, many imported SKUs still sit in a Sinopharm warehouse before a county or tertiary dock will accept them.
03	Mindray	Shenzhen	Local	Patient monitoring, ultrasound, anaesthesia and in-vitro diagnostics	Shenzhen house that county and many tertiary hospitals now specify for monitoring and mid-tier ultrasound ahead of the import majors.
04	United Imaging	Shanghai	Local	CT, MRI, PET/CT and radiotherapy systems	Shanghai imaging challenger that provincial substitution lots have pulled into rooms GE and Siemens once treated as uncontested.
05	MicroPort	Shanghai	Local	Coronary stents, orthopaedics, rhythm management and surgical robots	VBP-era stent and implant competitor; BioNixus tracks which provincial alliances it won, not a national share slide.
06	Weigao	Weihai	Local	Infusion consumables, orthopaedics and blood-management devices	Weihai volume manufacturer that public-hospital VBP lots keep pulling onto wards when import prices fail the bid floor.
07	Yuwell	Jiangsu	Local	Homecare oxygen, glucose, blood-pressure and mobility devices	Retail and homecare name more than a tertiary cath-lab name; hospital briefs should not file it as a Mindray peer.
08	Neusoft Medical	Shenyang	Local	Mid-tier CT, MRI and healthcare IT	Northeast imaging house that county upgrade programmes still shortlist when a United Imaging or import quote overshoots the budget.
09	Shinva	Zibo	Local	Sterilizers, infection-control and hospital-engineering systems	Zibo sterilizer installed base is a CSSD fact, not a brochure claim; replacement cycles follow infection-control audits.
10	GE HealthCare China	Beijing / Shanghai	MNC	Premium imaging, ultrasound and monitoring	Still wins high-end tertiary rooms; loses more county and substitution lots than a global deck usually prints.
11	Siemens Healthineers China	Shanghai	MNC	Imaging, laboratory diagnostics and radiotherapy	Shanghai commercial seat defends premium CT/MR and lab; provincial packages now score a domestic alternative beside it.
12	Philips Greater China (Health Systems)	Shanghai	MNC	Imaging, monitoring and health informatics	Monitoring and ultrasound seats in tier-1 teaching hospitals; county substitution language has narrowed the mid-tier book.
13	Provincial volume-based procurement alliances	Multiple provinces	Government	Alliance tenders that set public-hospital implant and consumable prices	The bid that resets a stent or infusion price across a province or a multi-province bloc; losing it is not a soft quarter.
14	Regional device dealers (provincial specialists)	Provincial capitals	Distributor	Installation, service and hospital relationships beside Sinopharm	County hospitals still pay a local dealer who holds the service van; BioNixus scores those vans by province, not by a Shanghai HQ slide.
15	Lepu Medical	Beijing	Local	Cardiovascular devices, IVD and surgical consumables	Beijing cardiovascular house that appears on the same VBP shortlists as MicroPort when a provincial stent lot opens.
16	Tertiary hospital equipment committees (class-A examples)	Beijing / Shanghai / Guangzhou	Operator	In-hospital capital committees that still specify premium imaging	The committee that can still buy a Siemens or GE gantry when the provincial package would have forced a domestic mid-tier unit.

Primary research

These are the medical device companies accounts we study in China

Need account-level or SKU-level data for a brand in China? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in China?

Primary research, market access & HEOR. Proposals within 48 hours.

Top market research companies in China (2026)

How the market is structured

NMPA file, provincial bid, Sinopharm warehouse

A foreign or domestic device that will be used in a Chinese public hospital needs an NMPA registration — Class I filing, Class II provincial or NMPA review, Class III NMPA review — held by a Chinese legal entity. That certificate does not put a scanner in a county CT room. Capital equipment is bought by the hospital’s equipment committee and the local health-commission budget, increasingly inside provincial or multi-province package tenders that score domestic substitution, service coverage and price. Mindray and United Imaging have used that scoring to take monitoring, ultrasound and mid-tier CT/MR lots that GE, Siemens and Philips used to treat as theirs. Consumables, stents, orthopaedic implants and infusion sets now live inside volume-based procurement: a provincial or alliance bid sets a price, winning SKUs take the public volume, and losing SKUs retreat to private hospitals and cash-pay wings. Weigao and MicroPort have learned to win those bids; multinational implant books have learned to lose them. Sinopharm’s device-distribution companies, together with regional dealers, hold the warehouse and the hospital invoice after the bid. Yuwell sits closer to the retail and homecare channel — glucose, oxygen, wheelchairs — than to the tertiary cath lab. Shinva still owns a large sterilizer and hospital-engineering installed base. Neusoft Medical competes in mid-tier imaging. BioNixus reconstructs the named provincial alliance, the named tertiary committee and the named Sinopharm or dealer warehouse before a China volume number is put in a deck.

Local

Shenzhen, Shanghai, Weihai and Zibo manufacturers that provincial substitution and VBP lots have pulled onto county and tertiary lists.

Mindray
United Imaging
MicroPort
Weigao
Yuwell
Neusoft Medical
Shinva
Lepu Medical

Multinational

GE, Siemens and Philips seats that still hold premium tier-1 rooms and now bid against domestic scoring in the same provincial packages.

GE HealthCare China
Siemens Healthineers China
Philips Greater China (Health Systems)

Regional

Provincial dealers who hold the service van and the county invoice when Sinopharm is the wholesaler but not the last mile.

Distributors & service partners

NMPA as the Class II/III gate, provincial VBP alliances as the price setter, Sinopharm as the state warehouse.

NMPA (National Medical Products Administration)
Sinopharm medical device distribution
Provincial volume-based procurement alliances
Regional device dealers (provincial specialists)
Tertiary hospital equipment committees (class-A examples)

What is moving

What is moving the medical device market in China

County-hospital upgrade programmes

Health-commission budgets for county CT, monitoring and ultrasound now score domestic service coverage; Mindray and United Imaging have used that score.

Volume-based procurement for implants and consumables

Provincial and alliance bids reset stent, orthopaedic and infusion prices; MicroPort, Weigao and Lepu treat those bids as the year, not as a side channel.

NMPA review timelines and local-entity rules

A foreign brand without a Chinese registrant and a post-market team does not reach the provincial envelope, however strong the overseas certificate looks.

Premium tertiary rooms versus substitution lots

Class-A teaching hospitals still specify import imaging; the same province’s county package may forbid it. BioNixus splits those two rooms in every forecast.

BioNixus fieldwork

How BioNixus studies medical device companies in China

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in China:

Provincial VBP award reconstructions so a MicroPort or Weigao “win” is tied to a named alliance, not a national average.
County-hospital imaging and monitoring walks that separate Mindray and United Imaging rooms from leftover import installed base.
Tertiary equipment-committee interviews in Beijing, Shanghai and Guangzhou on when a Siemens or GE gantry is still specifiable.
Sinopharm warehouse versus provincial-dealer service-van mapping for the SKUs that actually reach the dock.

Healthcare market research in China

Questions

Frequently Asked Questions

How are medical devices registered in China?

NMPA classifies them. Class I is a filing; Class II and III need review held by a Chinese legal entity. Provincial bureaus handle many Class II files and the inspections that follow.

What is volume-based procurement for devices?

Provincial or multi-province alliances tender a price for implants and consumables. Winning SKUs take the public-hospital volume; losing SKUs retreat to private and cash-pay wings.

Do GE, Siemens and Philips still win Chinese imaging lots?

Yes in tier-1 teaching-hospital rooms. County and substitution packages increasingly award Mindray, United Imaging or Neusoft Medical on service and price scores.

What is Sinopharm’s role in devices?

Its device-distribution arms warehouse and invoice many imported and some domestic SKUs after NMPA approval. Provincial dealers still own a share of county last-mile and service.

What does BioNixus study on Chinese device accounts?

Named provincial VBP reconstructions, tertiary equipment-committee interviews, county installed-base walks, and Sinopharm-versus-dealer warehouse mapping.

Is this a national share ranking of Chinese medtech?

No. Companies are listed by role because they recur in BioNixus hospital fieldwork and on NMPA-visible files; order is not a league table.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in China. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: NMPA — National Medical Products Administration, medical device registration and supervision, consulted 2026-09-05. Company classification (Local / MNC / Regional / distributors & service partners) reflects ownership and role in China, not size.

NMPA medical-device registration and classification notices, consulted 2026
Provincial volume-based procurement alliance award notices for stents, orthopaedics and infusion
Mindray, United Imaging, MicroPort, Weigao, Yuwell, Neusoft Medical and Shinva published company descriptions
BioNixus China tertiary and county hospital fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need device-level competitive data in China?

Installed base, procedure volumes, surgeon preference and tender outcomes by hospital — fielded across public and private operators.

Planning research in China?

Primary research, market access & HEOR. Proposals within 48 hours.

Medical Device Companies in China

Top medical device companies in China

These are the medical device companies accounts we study in China

Planning research in China?

NMPA file, provincial bid, Sinopharm warehouse

Local

Multinational

Regional

Distributors & service partners

What is moving the medical device market in China

County-hospital upgrade programmes

Volume-based procurement for implants and consumables

NMPA review timelines and local-entity rules

Premium tertiary rooms versus substitution lots

How BioNixus studies medical device companies in China

Related research and directories

More company directories for China

Frequently Asked Questions

Data sources & methodology

Need device-level competitive data in China?

Planning research in China?